Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bemnifosbuvir in high-risk outpatients with COVID-19
2023-504540-33-00Phase 3Completed
- Sponsor
- Atea Pharmaceuticals Inc.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Bemnifosbuvir with Placebo (2 arms). Primary endpoint: Hospitalization for any cause or death through Day 29. Started Mar 2023; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-504540-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504540-33-00.